JAMA carries a meta-review of interventions to improve adherence to drug regimens.
Read More
A study carried by the Journal of the American Medical Association reveals the absurd and despicable profits being earned by drug companies off the misery of cancer patients.
Among its other defects, it appears that Medicare’s hospital readmissions reduction program may have led to an increase in mortality.
A Deloitte annual report looks at drug manufacturer returns on research and development activities.
A new survey from the Employee Benefits Research Institute continues to find that persons covered by high deductible plans are more engaged with their health and health care.
As might be expected in a sector that represents 20% of the economy, there was a lot going on in health care in 2018.
I got very preoccupied with a number of matters leading up to the holiday and wasn’t able to keep up my posting schedule and I failed to get a holiday post out!!
So I am slightly making up for it now by wishing that you all had a relaxing Christmas and are enjoying this lull before New Year’s Day and then the dreaded return to work and winter. I hope you all can find what is important in life and take pleasure in that and do you best to ignore those items that cause you unhappiness. Most of all, I hope you find joy in the company of friends and family.
A new study examines factors which may linked to variations in end-of-life cancer care spending.
A study from BRG confirms that hospitals are making the most of their profit opportunities in the 340B program.
About this Blog
The Healthy Skeptic is a website about the health care system, and is written by Kevin Roche, who has many years of experience working in the health industry. Mr. Roche is available to assist health care companies through consulting arrangements through Roche Consulting, LLC and may be reached at khroche@healthy-skeptic.com.